The company announced the completion of enrollment in its PEAK trial, a pivotal study for patients with imatinib-resistant gastrointestinal stromal tumors, and the initiation of a Phase 1 trial for a ...

He worked with chemists at Novartis to develop a drug that would bind to the mutant protein like a key in a lock. Novartis ...

Business Highlights & Milestones Completed enrollment in PEAK, a randomized, open-label, global Phase 3 trial evaluating bezuclastinib in combination with sunitinib vs sunitinib alone in patients with ...

Imatinib is a specific tyrosine kinase inhibitor which has been approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia and c-KIT (CD117)-positive gastrointestinal ...

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a do ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

Novartis has received FDA accelerated approval for Scemblix (asciminib) to treat adults with newly diagnosed Ph+ CML-CP.

Duke-NUS scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance ...

More than 95% of chronic myeloid leukemia (CML) and 20%-30% of acute lymphoblastic leukemia (ALL) patients express the fusion ...